May 26, 2010 - Data Presented at EuroPCR 2010 Demonstrate Effectiveness of OrbusNeich's Genous™ Bio-engineered R stent™ in Diabetic Patients – OrbusNeich announced that 12-month follow-up data from a subset analysis of the global e-HEALING registry demonstrate that the company’s Genous Bio-engineered R stent is effective in diabetic patients.Peter Damman, M.D., of the Academic Medical Center in Amsterdam presented the subset analysis from 1,236 diabetic patients, including 273 insulin dependent diabetics (IDD) and 963 non-insulin dependent diabetics (NIDD), from the e-HEALING clinical registry and found a target vessel failure (TVF) rate of 10 percent for diabetic patients, compared to 7.9 percent for non-diabetics at 12 months. Specifically, the TVF rate in IDD was 13.4 percent, compared to 9 percent in NIDD. The higher TVF rates in diabetic patients were mainly driven by a higher mortality hazard. The target lesion revascularization rate (TLR) was 6.4 percent in diabetics, which is comparable to a reported 5.4 percent in non-diabetic patients, and the definite or probable stent thrombosis rate at 12 months was similar with 1.2 percent in diabetics compared to 1.1 percent in non-diabetics... [PDF] OrbusNeich's Press Release -
